Clinical Trials Directory

Trials / Completed

CompletedNCT06336512

Trimester Sequential Estimation of Serum Zonulin as a Predictor of Gestational Diabetes Mellitus

Trimester Sequential Estimation of Serum Zonulin Overrides Glucose Homeostasis Biomarkers for Prediction of Gestational Diabetes Mellitus

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
70 (actual)
Sponsor
Benha University · Academic / Other
Sex
Female
Age
22 Years – 50 Years
Healthy volunteers
Accepted

Summary

Gestational diabetes mellitus (GDM) is the development of glucose intolerance (GI) during pregnancy in a previously normoglycemic (NG) woman and associated with insulin resistance (IR). GDM is the most prevalent metabolic disorder during pregnancy and became a major public health problem for being usually diagnosed and detected after 24 gestational weeks (GW), while its complications can occur much earlier and this may explain its burden on maternal and fetal welfare. Human zonulin is a surrogate marker of intestinal permeability and can be utilized as biomarker for intestinal barrier function. Zonulin-mediated increase in intestinal permeability plays a role in the pathogenesis of insulin resistance, obesity, DM and metabolic syndrome. The increasing global prevalence of GDM with its associated risk of poor pregnancy and long-term risks for the mother and the offspring may lead to the production of new generation of diabetics.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTELISAEstimation of Zonulin by ELISA from the Blood samples which were obtained at time of pregnancy .

Timeline

Start date
2023-01-15
Primary completion
2023-07-01
Completion
2023-10-01
First posted
2024-03-28
Last updated
2024-03-28

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06336512. Inclusion in this directory is not an endorsement.